Corbevax

[7][8] The vaccine consists of a version of the receptor binding domain (RBD) of the SARS‑CoV‑2 spike protein, together with the adjuvants aluminium hydroxide gel and CpG 1018.

[9] Researchers at the Precision Vaccine Program at Boston Children's Hospital and Harvard Medical School, in Boston, Massachusetts, in collaboration with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas, undertook a screening process that compared multiple molecules head-to-head in different combinations.

[2] In April 2021, the U.S. International Development Finance Corporation (DFC) announced that it would fund the expansion of Biological E's manufacturing capabilities, so that it could produce at least 1 billion doses by the end of 2022.

[12][13][14] In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials.

A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global Phase III study.